Academic Journal
The effectiveness of red-light therapy on myopia control depends on its direct effect: a mediation analysis.
| Τίτλος: | The effectiveness of red-light therapy on myopia control depends on its direct effect: a mediation analysis. |
|---|---|
| Συγγραφείς: | Chen Q; Department of Ophthalmology, The First Affiliated Hospital with Nanjing Medical University, 300 Guangzhou Road, Nanjing, Jiangsu, 210029, China., Wei H; Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, Yunnan, 650032, China.; Department of Ocular Epidemiology, Singapore Eye Research Institute, 20 College Road, Singapore, 169856, Singapore., Soh ZD; Department of Ocular Epidemiology, Singapore Eye Research Institute, 20 College Road, Singapore, 169856, Singapore., Zhu Q; Department of Pediatric Ophthalmology, Affiliated Hospital of Yunnan University, 176 Qingnian Road, Kunming, Yunnan, 650021, China., Shao X; Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, Yunnan, 650032, China., Xue C; Department of Ocular Epidemiology, Singapore Eye Research Institute, 20 College Road, Singapore, 169856, Singapore., Li H; Department of Ocular Epidemiology, Singapore Eye Research Institute, 20 College Road, Singapore, 169856, Singapore., Tao Y; Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, Yunnan, 650032, China., Hu M; Department of Pediatric Ophthalmology, Affiliated Hospital of Yunnan University, 176 Qingnian Road, Kunming, Yunnan, 650021, China., Cheng CY; Department of Ocular Epidemiology, Singapore Eye Research Institute, 20 College Road, Singapore, 169856, Singapore.; Ophthalmology & Visual Sciences Academic Clinical Program, Duke-NUS Medical School, 8 College Road, Singapore, 169857, Singapore.; Centre for Innovation and Precision Eye Health, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 7, Singapore, 119228, Singapore.; Department of Ophthalmology, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 7, Singapore, 119228, Singapore., Zhong H; Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, 295 Xichang Road, Kunming, Yunnan, 650032, China. zhoculist@163.com. |
| Πηγή: | Journal of translational medicine [J Transl Med] 2025 Dec 02; Vol. 24 (1), pp. 34. Date of Electronic Publication: 2025 Dec 02. |
| Τύπος έκδοσης: | Journal Article; Randomized Controlled Trial; Multicenter Study; Research Support, Non-U.S. Gov't |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: [London] : BioMed Central, 2003- |
| Ιατρικοί όροι (MeSH): | Myopia*/therapy , Myopia*/physiopathology , Red Light*, Choroid/pathology ; Refraction, Ocular/radiation effects ; Humans ; Female ; Treatment Outcome ; Male ; Child |
| Περίληψη: | PURPOSE: To investigate whether alterations in subfoveal choroidal thickness (SFCT) and peripheral retinal refraction mediate the efficacy of repeated low-level red-light (RLRL) therapy for myopia control. METHODS: We conducted a mediation analysis within a multicenter, randomized controlled trial. A total of 300 myopic children were included in this analysis. Participants in RLRL group wore single-vision spectacles (SVSs) and received red-light therapy twice daily for 12 months. The control group wore SVSs only, without any additional myopia-control intervention. Axial length (AL), spherical equivalent refraction (SER), SFCT and total refractive difference value (TRDV) were measured at baseline and at follow-up visits over 12 months. RESULTS: After 12 months, RLRL therapy significantly attenuated axial length and myopic shift in spherical equivalence compared with controls, accompanied by sustained increases in choroidal thickness and reductions in peripheral hyperopic defocus. Mediation analysis revealed that changes in choroidal thickness and peripheral refraction accounted for 24.83% and 6.79%, respectively, of the effect on axial length inhibition, and 28.79% and 5.97% of the effect on spherical equivalent control. The remaining effects were attributable to the direct impact of red-light (68.39% for axial length and 65.24% for spherical equivalence). Notably, choroidal thickening emerged as the predominant mediator within the first three months. CONCLUSIONS: RLRL therapy exerted a predominantly direct effect on myopia control, while changes in choroidal thickness and peripheral defocus partially mediated its effectiveness. TRIAL REGISTRATION: This trial was registered at the Chinese Clinical Trial Registry on January 30, 2021, with trial registration number: ChiCTR2100042836. https://www.chictr.org.cn/showprojEN.html?proj=120971 . |
| Competing Interests: | Declarations. Ethics approval and consent to participate: The study was approved by the Second People’s Hospital of Yunnan Province Ethics Committee (Grant No. 2020133) and adhered to the tenets of the Declaration of Helsinki. The participants’ guardians provided written informed consent prior to enrollment in the RCT. This trial was conducted in accordance with the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines. Consent for publication: Not applicable. Competing interests: The authors have no proprietary or commercial interest in any materials discussed in this article. |
| References: | Photodiagnosis Photodyn Ther. 2025 Aug;54:104651. (PMID: 40449858) Asia Pac J Ophthalmol (Phila). 2023 Jul-Aug 01;12(4):377-383. (PMID: 37523429) Int J Mol Sci. 2025 Jan 02;26(1):. (PMID: 39796188) Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M20-M30. (PMID: 30817826) Ophthalmology. 2023 Mar;130(3):286-296. (PMID: 36240954) Photodiagnosis Photodyn Ther. 2024 Dec;50:104412. (PMID: 39579842) Curr Eye Res. 2016 May;41(5):708-14. (PMID: 25860873) Ophthalmic Physiol Opt. 2015 Jul;35(4):405-13. (PMID: 26010292) Am J Ophthalmol. 2022 May;237:130-138. (PMID: 34942105) Acta Ophthalmol. 2019 May;97(3):e454-e459. (PMID: 30288939) Invest Ophthalmol Vis Sci. 2022 Jan 3;63(1):8. (PMID: 34989760) JAMA Ophthalmol. 2022 Feb 01;140(2):162-169. (PMID: 34989764) Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M106-M131. (PMID: 30817829) Int J Ophthalmol. 2024 Feb 18;17(2):247-256. (PMID: 38371246) Exp Eye Res. 2019 Dec;189:107850. (PMID: 31639338) Biomed Pharmacother. 2022 Jan;145:112472. (PMID: 34861634) Int J Med Sci. 2023 Sep 4;20(10):1363-1376. (PMID: 37786442) Neuron. 2004 Aug 19;43(4):447-68. (PMID: 15312645) Asia Pac J Ophthalmol (Phila). 2024 Nov-Dec;13(6):100124. (PMID: 39672511) Exp Eye Res. 2009 Jun;88(6):1092-9. (PMID: 19450449) Ophthalmology. 2022 May;129(5):509-519. (PMID: 34863776) Invest Ophthalmol Vis Sci. 2007 Sep;48(9):3914-22. (PMID: 17724167) Eur J Neurosci. 2005 Apr;21(8):2199-208. (PMID: 15869516) Exp Eye Res. 2018 Nov;176:147-160. (PMID: 29981345) BMC Ophthalmol. 2020 Apr 15;20(1):152. (PMID: 32295547) Surv Ophthalmol. 2020 Jul - Aug;65(4):473-486. (PMID: 31923478) Acta Ophthalmol. 2024 May;102(3):349-356. (PMID: 37565361) Front Med (Lausanne). 2021 Dec 09;8:777685. (PMID: 34957151) J Clin Med. 2025 Jan 21;14(3):. (PMID: 39941333) Asia Pac J Ophthalmol (Phila). 2025 Mar-Apr;14(2):100115. (PMID: 39626798) JAMA Ophthalmol. 2025 Jun 1;143(6):480-488. (PMID: 40272813) Int J Ophthalmol. 2024 Feb 18;17(2):324-330. (PMID: 38371262) Optom Vis Sci. 2004 Feb;81(2):111-8. (PMID: 15127930) Vis Neurosci. 2005 May-Jun;22(3):251-61. (PMID: 16079001) Biomed Res Int. 2014;2014:639160. (PMID: 25013793) J Clin Med. 2022 Dec 17;11(24):. (PMID: 36556114) Optom Vis Sci. 2015 Mar;92(3):258-66. (PMID: 25611765) JAMA Netw Open. 2023 Apr 3;6(4):e239612. (PMID: 37099298) Front Med (Lausanne). 2023 Oct 20;10:1241352. (PMID: 37928462) Lasers Surg Med. 2020 Sep;52(7):671-681. (PMID: 31820475) Exp Eye Res. 2012 Oct;103:33-40. (PMID: 22960317) Graefes Arch Clin Exp Ophthalmol. 2023 Feb;261(2):575-584. (PMID: 35976467) JAMA Ophthalmol. 2023 Jul 1;141(7):693-695. (PMID: 37227712) Invest Ophthalmol Vis Sci. 2014 Sep 04;55(10):6765-73. (PMID: 25190657) |
| Grant Information: | 82360212 National Natural Science Foundation of China-Yunnan Joint Fund |
| Contributed Indexing: | Keywords: Choroidal thickness; Mediation analysis; Myopia control; Peripheral retinal refraction; Repeated low-level red-light therapy |
| Entry Date(s): | Date Created: 20251203 Date Completed: 20260626 Latest Revision: 20260912 |
| Update Code: | 20260912 |
| PubMed Central ID: | PMC12777278 |
| DOI: | 10.1186/s12967-025-07514-y |
| PMID: | 41331814 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1479-5876 |
|---|---|
| DOI: | 10.1186/s12967-025-07514-y |